BLPH Bellerophon Therapeutics Inc

USD 0.05 0.00 0
Icon

Bellerophon Therapeutics Inc (BLPH) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | OTC
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.05

0.00 (0.00)%

USD 0.62M

1.00K

N/A

N/A

Icon

BLPH

Bellerophon Therapeutics Inc (USD)
COMMON STOCK | OTC
USD 0.05
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.62M

N/A

USD 0.05

Bellerophon Therapeutics Inc (BLPH) Stock Forecast

N/A

Based on the Bellerophon Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Bellerophon Therapeutics Inc is not available over the next 12 months. Bellerophon Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Bellerophon Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Bellerophon Therapeutics Inc’s stock price was USD 0.051. Bellerophon Therapeutics Inc’s stock price has changed by +2.00% over the past week, -19.69% over the past month and -93.26% over the last year.

No recent analyst target price found for Bellerophon Therapeutics Inc
No recent average analyst rating found for Bellerophon Therapeutics Inc

Company Overview Bellerophon Therapeutics Inc

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatm...Read More

https://bellerophon.com

20 Independence Boulevard, Warren, NJ, United States, 07059

18

December

USD

USA

Adjusted Closing Price for Bellerophon Therapeutics Inc (BLPH)

Loading...

Unadjusted Closing Price for Bellerophon Therapeutics Inc (BLPH)

Loading...

Share Trading Volume for Bellerophon Therapeutics Inc Shares

Loading...

Compare Performance of Bellerophon Therapeutics Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BLPH

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Bellerophon Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF
Novo Nordisk A/S 0.00 (0.00%) USD632.23B 48.44 4.92

ETFs Containing BLPH

Symbol Name BLPH's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Bellerophon Therapeutics Inc (BLPH) Stock

Stock Target Advisor's fundamental analysis for Bellerophon Therapeutics Inc's stock is Slightly Bearish.

Unfortunately we do not have enough data on BLPH's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on BLPH's stock to indicate what its average analyst target is.

BLPH stock's Price/Earning ratio is 5.29. Our analysis grades BLPH stock's Price / Earning ratio at D-. This means that BLPH stock's Price/Earning ratio is above 38% of the stocks in the Biotechnology sector in the OTC exchange. Based on this BLPH may be fairly valued for its sector

The last closing price of BLPH's stock was USD 0.05.

The most recent market capitalization for BLPH is USD 0.62M.

Unfortunately we do not have enough analyst data on BLPH's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Bellerophon Therapeutics Inc's stock.

As per our most recent records Bellerophon Therapeutics Inc has 18 Employees.

Bellerophon Therapeutics Inc's registered address is 20 Independence Boulevard, Warren, NJ, United States, 07059. You can get more information about it from Bellerophon Therapeutics Inc's website at https://bellerophon.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...